您好, 歡迎來到環(huán)保在線! 登錄| 免費(fèi)注冊| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:深圳艾利蒙生物科技有限公司>>技術(shù)文章>>替格瑞洛雜質(zhì) 全套對(duì)照品
替格瑞洛雜質(zhì) 全套對(duì)照品
深圳艾利蒙生物科技有限公司可提供替格瑞洛雜質(zhì)全套,并隨貨提供COA證書,HPLC,NMR,MS圖譜,10mg/25mg/50mg/100mg等多種規(guī)格可選。
部分雜質(zhì)長期備有現(xiàn)貨,可快速發(fā)貨,并可根據(jù)客戶需要提供雜質(zhì)定制服務(wù)。
替格瑞洛的相關(guān)介紹:
中文名稱:替格瑞洛
中文別名:(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-二氟苯基)環(huán)丙基]氨基]-5-丙硫基三唑并[4,5-d]嘧啶-3-基]-5-(2-羥乙氧基)-1,2-環(huán)戊二醇; 替卡格雷;
英文名稱:ticagrelor
英文別名:Brilique; AZD 6140; TICARGRELOR;
Brilinta; Ticagrelor;
CAS號(hào):274693-27-5
分子式:C23H28F2N6O4S
分子量:522.56800
結(jié)構(gòu)式:
適應(yīng)癥:
本品用于急性冠脈綜合征(不穩(wěn)定性心絞痛、非ST段抬高心肌梗死或ST段抬高心肌梗死)患者,包括接受藥物治療和經(jīng)皮冠狀動(dòng)脈介入(PCI)治療的患者,降低血栓性心血管事件的發(fā)生率。與氯吡格雷相比,本品可以降低心血管死亡、心肌梗死或卒中復(fù)合終點(diǎn)的發(fā)生率,兩治療組之間的差異來源于心血管死亡和心肌梗死,而在卒中方面無差異。
在ACS患者中,對(duì)本品與阿司匹林聯(lián)合用藥進(jìn)行了研究。結(jié)果發(fā)現(xiàn),阿司匹林維持劑量大于100 mg會(huì)降低替格瑞洛減少復(fù)合終點(diǎn)事件的臨床療效,因此,阿司匹林的維持劑量不能超過每日100 mg。
替格瑞洛雜質(zhì) 全套對(duì)照品
替格瑞洛雜質(zhì)為我司優(yōu)勢雜質(zhì),長期備有庫存,發(fā)貨快。雜質(zhì)結(jié)構(gòu)式及更多其他雜質(zhì)對(duì)照品,可進(jìn)入我公司展臺(tái)詳細(xì)查看。
附:替格瑞洛雜質(zhì)列表:
中文名稱 | 英文名稱 |
替格瑞洛標(biāo)準(zhǔn)品 | Ticagrelor |
替格瑞洛雜質(zhì)1 | (1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)2 | (1S,2S,3R,5S)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)3 | (1R,2R,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)4 | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) |
替格瑞洛雜質(zhì)5 | (1R,2R,3S,5R)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1R,2R,3S,5R)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) |
替格瑞洛雜質(zhì)6 | 2-(((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl acetate |
替格瑞洛雜質(zhì)7 | (1S,2S,3R,5S)-3-(7-hydroxy-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)8 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)9 | 2-(((3aR,4S,6R,6aS)-6-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
替格瑞洛雜質(zhì)10 | 5-amino-6-chloro-2-(propylthio)pyrimidin-4-ol |
替格瑞洛雜質(zhì)11 | 2-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)oxy)ethanol |
替格瑞洛雜質(zhì)12 | (1S,2S,3R,5S)-3-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)13 | 5-amino-6-(((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)amino)-2-(propylthio)pyrimidin-4-ol |
替格瑞洛雜質(zhì)14 | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)15 | (1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-methoxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)16 | 2-(((3aS,4R,6S,6aR)-6-((3-((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
替格瑞洛雜質(zhì)17 | (1R,2R,3S,5R)-3-((3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)18 | (1S,2S,3R,5S)-3-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)19 | (1S,2S,3R,5S)-3-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)20 | (1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol |
替格瑞洛雜質(zhì)21 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)22 | (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)23 | sodium 7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-olate |
替格瑞洛雜質(zhì)24 | (1S,2S,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)25 | (1S,2S,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)26 | 2-((6-chloro-5-(7-(2-hydroxyethoxy)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2-(propylthio)pyrimidin-4-yl)oxy)ethanol |
替格瑞洛雜質(zhì)27 | (1S,2S,3S,5R)-3-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)28 | 7-chloro-3-(4,6-dichloro-2-(propylthio)pyrimidin-5-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine |
替格瑞洛雜質(zhì)29 | (1S,2S,3R,5S)-3-(2-hydroxyethoxy)-5-(5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2-diol |
替格瑞洛雜質(zhì)30 | 2-(((3aR,4R,6S,6aS)-6-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol |
深圳艾利蒙生物科技有限公司主營醫(yī)藥標(biāo)準(zhǔn)品及雜質(zhì)對(duì)照品,所有雜質(zhì)均提供HPLC,NMR,MS圖譜及CoA證: 舒更葡糖鈉雜質(zhì),骨化三醇雜質(zhì),阿法骨化醇雜質(zhì),艾地骨化醇雜質(zhì),西格列汀雜質(zhì),利伐沙班雜質(zhì),依托考昔雜質(zhì),左氧氟沙星雜質(zhì),阿加曲班雜質(zhì),利奈唑胺雜質(zhì),匹伐他汀雜質(zhì),利格列汀雜質(zhì),替格瑞洛雜質(zhì),阿哌沙班雜質(zhì),西他沙星雜質(zhì),伊馬替尼雜質(zhì),洛索洛芬鈉雜質(zhì),普瑞巴林雜質(zhì),環(huán)苯扎林雜質(zhì),鹽酸帕洛諾司瓊雜質(zhì)等。
請(qǐng)輸入賬號(hào)
請(qǐng)輸入密碼
請(qǐng)輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),環(huán)保在線對(duì)此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險(xiǎn),建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。